p57 (Kip2, cyclin-dependent kinase inhibitor 1C), often found downregulated in cancer, is reported to hold tumor suppressor properties. Originally described as a cyclin-dependent kinase (cdk) inhibitor, p57 KIP2 has since been shown to influence other cellular processes, beyond cell cycle regulation, including cell death and cell migration. Inhibition of cell migration by p57 KIP2 is attributed to the stabilization of the actin cytoskeleton through the activation of LIM domain kinase-1 (LIMK-1). Furthermore, p57
p57 (Kip2, cyclin-dependent kinase inhibitor 1C) has been described as a potential tumor suppressor gene due to its ability to inhibit several of the hallmarks of cancer. 1 The importance of p57 KIP2 in the suppression of cancer is highlighted by its mutation/inactivation in Beckwith-Wiedemann Syndrome, a cancer pre-disposing syndrome, 2 and its reported decrease in protein expression in cancers of the breast, lung, liver, and prostate, among others. [3] [4] [5] [6] [7] [8] Inhibition of p57 KIP2 expression in cancer cells is mediated by promoter DNA methylation at CpG islands and/or by histone modifications, such as methylation and deacetylation. 1 Worth a notice, the lack of p57 KIP2 expression in tumors is associated with poor survival, and has been identified as prognostic marker for many of the aforementioned cancer types. 1 Initially identified as a member of the Cip/Kip family of Cdk (cyclin-dependent kinase) inhibitors, 9 ,10 p57 KIP2 has since been shown to have diverse cellular roles aside from cell cycle inhibition, for example, promotion of cell death, [11] [12] [13] inhibition of cell migration, 14 and regulation of cell differentiation. [15] [16] [17] Indeed, considering that p57 KIP2 null mice have increased embryonic lethality and gross developmental defects as compared with p21 CIP1/CDKN1A and p27 KIP2/CDKN1B null mice, it appears that the cellular roles of p57 KIP2 surpass that of the other Cdk inhibitors. [18] [19] [20] The ease at which cancer cells migrate and invade a neighboring tissue demonstrates the importance of regulators of cell cytoskeleton structure in the cancer progression. The cytoskeleton remodeling factor cofilin disassembles actin filaments and thereby facilitates cell migration through increasing the actin mobile fraction. 21 Active unphosphorylated cofilin is associated with increased tumor metastasis. 22 Cofilin can be inactivated by LIM domain kinase-1/2 (LIMK-1/2), 23, 24 which are themselves activated by phosphorylation on Thr508 25 through the Rho/Rho kinase (ROCK) signaling pathway. 26 Interestingly, p57 KIP2 interacts with LIM domain kinase-1 (LIMK-1) and increases its kinase activity independently of Rho/ROCK signaling and thereby contributes to the stabilization of actin filaments and the inhibition of cell migration. 14 p57
KIP2 expression can enhance cell death induced by staurosporine (STS) and DNA damaging agents such as etoposide and cisplatin, all of which induce apoptotic mitochondrial events. 11, 12 In contrast, p57 KIP2 has no potentiating effect on apoptosis induced by death receptor ligand, 12 indicating that p57 KIP2 enhances cell death specifically at the level of the mitochondria. Indeed, overexpression of Bcl-2 or 's cell death promoting effect. 12 Interestingly, there are reports that actin can influence the conductance of VDAC channels. In Neurospora crassa, an abundance of monomeric actin facilitated the closure of VDAC channels, whereas stable filamentous actin (F-actin) was unable to do the same. 27 In fact, the presence of F-actin led to an increased ion conductance across the outer mitochondrial membrane. This indicated a possible link between the stability of actin cytoskeleton and the integrity of the mitochondrial transmembrane potential. In this study, we investigated the possibility that the cell death promoting effect of p57 KIP2 requires its actin cytoskeleton-stabilizing effect.
Results

p57
KIP2 stabilizes the actin cytoskeleton and promotes apoptosis. Two of the tumor suppressor characteristics of p57 KIP2 include inhibition of cell migration and promotion of apoptosis. 11, 12, 14 In this study, we took advantage of HeLa Tet-On derived cell line stably transfected with tetracyclineinducible p57 KIP2 , HeLa-p57 KIP2 cells. These cells can be induced to express p57 KIP2 selectively, upon administration of the tetracycline analog doxycycline (Dox) (Figure 1a) . Induction of p57 KIP2 expression in HeLa-p57 KIP2 cells led to an increased formation of actin stress fibers as visualized by staining with phalloidin, which binds F-actin (Figure 1b) . Additionally, fluorescence recovery after photobleaching (FRAP) analysis of green fluorescence protein (GFP)-labeled-actin revealed a reduced actin-GFP mobile fraction in HeLa-p57 KIP2 cells treated with Dox as compared with untreated cells, providing additional evidence for the actin cytoskeleton-stabilizing function of p57 KIP2 (Figure 1c ). Although, induction of p57 KIP2 expression did not provoke cell death per se, it sensitized cells to apoptosis triggered by STS (Figures 1d and e, Supplementary Figure S1 ).
It has already been established that stabilization of the actin cytoskeleton can induce apoptotic cell death. 28, 29 Jasplakinolide (Jasp), an actin cytoskeleton-stabilizing agent, was used to investigate whether actin cytoskeleton stabilization increases cell death induced by STS, thereby mimicking the effect of p57 KIP2 . 30 At the concentration used in this study, Jasp stabilized the actin cytoskeleton, as shown by FRAP measurement of the mobility of actin-GFP (Figure 1c ), but did not increase cell death (Figures 1d and e, Supplementary  Figure S1 ). Pre-treatment of HeLa-p57 KIP2 cells with Jasp 30 min before STS treatment resulted in an increase in cells exhibiting apoptotic nuclear morphology (Figure 1d , Supplementary Figure S1 ) and poly ADP-ribose polymerase (PARP) cleavage (Figure 1e ), similar to levels observed in cells co-treated with Dox and STS. Importantly, induction of p57 KIP2 expression by Dox treatment did not significantly increase the cell death caused by Jasp and STS co-treatment indicating that indeed Jasp mimics the pro-apoptotic effect of p57 KIP2 .
Destabilization of actin filaments inhibits p57
KIP2 enhancement of STS-induced cell death. As actin cytoskeleton stabilization mimicked the pro-apoptotic effects of p57 KIP2 , an actin cytoskeleton destabilizing agent cytochalasin D (Cyto. D), 31 was used to investigate whether depolymerization of actin filaments could prevent the promotion of cell death by p57 KIP2 . Cyto. D was used at a concentration that does not induce cell death, but yet retains the ability to destabilize the actin cytoskeleton (Figures 2a-c (Figure 2c ). Therefore, one could conclude that actin cytoskeleton destabilization inhibits the ability of p57 KIP2 to enhance STS-induced apoptotic cell death.
LIMK-1 is required for p57
KIP2
-induced cell death. Activation of LIMK-1 kinase results in decreased cofilin activity through phosphorylation and as such, increased actin cytoskeleton stabilization. 26 It has previously been shown that p57
KIP2 directly interacts with LIMK-1 resulting in an increase in LIMK-1 kinase activity, which is required for p57 KIP2 -mediated actin cytoskeleton stabilization. 14 To investigate whether LIMK-1 is required for p57 KIP2 -mediated apoptosis, small interfering RNA (siRNA) directed against LIMK-1 were used, which resulted in the specific knockdown of LIMK-1 protein levels (Figure 3a) .
In HeLa-p57 KIP2 cells co-treated with Dox and STS, there was a reduction in the apoptotic nuclei to 6.7% in LIMK-1 knockdown cells as compared with 15.2% in LIMK-1 expressing cells (Figure 3b ). In fact, the number of apoptotic nuclei in LIMK-1 knockdown cells co-treated with Dox and STS were similar to those observed in cells treated only with STS ( Figure 3b) . Similarly, measurement of DEVDase activity also showed a decrease caspase-3 like activity in cells co-treated with Dox and STS when LIMK-1 expression was suppressed as compared with the control (Figure 3c ). Furthermore, analysis of PARP cleavage by immunoblot confirmed that in LIMK-1 deficient cells, p57 KIP2 was unable to enhance STSmediated cleavage of this caspase-3 substrate (Figure 3d) . Together, these results demonstrated that silencing of LIMK-1 prevented p57 KIP2 enhancement of STS-induced apoptosis. Thus, this additionally established that loss of the actinstabilizing effect of p57 KIP2 is sufficient to prevent its proapoptotic effect.
Actin cytoskeleton stabilization by p57 KIP2 positively modulates apoptosis at the mitochondrial level. So far, it has been established that the pro-apoptotic effect of p57 KIP2 requires its ability to stabilize the actin cytoskeleton. This death promoting effect of p57 KIP2 was previously shown to be mediated through the mitochondria. 12 Indeed treatment of HeLa-p57 KIP2 cells with Dox and STS increased the loss of mitochondrial transmembrane potential (DCm) compared with STS treatment alone (Figure 4a ). The importance of actin dynamic for maintenance of DCm is demonstrated by the ability of Jasp to enhance STS-induced loss in DCm (Figure 4b) , and of Cyto. D to reduce the loss of DCm induced by Dox and STS co-treatment (Figure 4c) . Furthermore, in the presence of a kinase-inactive mutant of LIMK-1 (LIMK-1-D460A), p57 KIP2 expression did not enhance STSinduced loss of DCm (Figure 4d ). In all, these results show that a stable actin cytoskeleton, induced by p57 KIP2 , positively modulates apoptosis at the mitochondrial level.
Actin stabilization by p57
KIP2 displaces hexokinase-1 (HK-1) from mitochondria. Previous work has shown that inhibition of VDAC channel opening using 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS) counteracts the p57 KIP2 -death promoting effect. 14 Therefore, the effect of p57 KIP2 on the mitochondrial protein levels of HK-1, an important regulator of VDAC channel conductance, was examined. A decrease in mitochondrial localization of HK-1 was observed upon Dox treatment of HeLap57 KIP2 cells (Figure 5a ), Actin cytoskeleton stabilization by Jasp also resulted in a decrease in mitochondrial HK-1 (Figure 5a) . Finally, the ability of HK-1 to rescue cells from apoptosis induced by p57 KIP2 was investigated. Accordingly, overexpression of HK-1 in p57 KIP2 expressing cells resulted in a decrease in cleaved caspase-3 staining compared with the pcDNA-transfected control (Figures 4b  and c) . 
Discussion
p57
KIP2 inhibits many of the hallmarks of cancer and as such has been hailed as a potential tumor suppressor gene. 1 The results in this study corroborate previous studies showing firstly that p57 KIP2 inhibits cancer cell migration through stabilization of the actin cytoskeleton, and secondly that p57 KIP2 enhances apoptotic cancer cell death through mitochondrial depolarization. This study examines the interplay between these two seemingly disparate functions of p57 KIP2 , and shows that the pro-apoptotic effect of p57 KIP2 depends on its ability to stabilize the actin cytoskeleton. Disturbing actin cytoskeleton dynamics affects the ability of p57 KIP2 to promote cell death. We here show that stabilizing the actin cytoskeleton mimics the death promoting effect of p57 KIP2 , and destabilizing actin filaments reverses this effect. Significantly, inhibition of the actin cytoskeleton-stabilizing effect of p57 KIP2 (through LIMK-1 knockdown) also abrogates the death promoting effect of p57 KIP2 , providing a direct link between the actin cytoskeletonstabilizing function of p57 KIP2 and the death promoting function of p57 KIP2 . Stabilization of actin cytoskeleton has been shown to induce cell death. 28, 32 Although to date, the mechanism by which F-actin sensitizes to cell death is not fully described, evidence suggests that it is through mitochondrial depolarization. 27, 32 Further investigation into how p57 KIP2 sensitizes cells to death revealed a link between actin cytoskeleton stabilization and mitochondrial hexokinase levels. Hexokinase is often found overexpressed in cancer cells, where its binding to mitochondria enhances the cell's rate of glycolysis through easy access to mitochondrial-generated ATP. 33 The closure of VDAC channels upon hexokinase binding is one mechanism used by cancer cells to evade death. 34 This study shows that actin cytoskeleton stabilization either by Jasp or by p57 KIP2 expression displaces HK-1 from the mitochondrial membrane. In fact, overexpression of HK-1 inhibits the promotion of cell death by p57 KIP2 . This describes a scenario whereby stabilization of actin by p57 KIP2 promotes cell death through the displacement of HK-1 from the mitochondria. Many cancer cells exhibit decreased p57 KIP2 expression either through promoter DNA methylation, histone modifications, genetic mutation, silencing by microRNA's, or proteasomal degradation. 1 Interestingly, induced p57 KIP2 expression in tumors forces regression of the cancer. 35 Therefore, as with many tumor suppressors, it is important for the cancer to keep expression of p57 KIP2 at a reduced level. Consequently, p57 KIP2 protein expression is being tested as a prognostic indicator in cancer. In this study, we have shown that the negative regulation of at least two cancer hallmarks, increased cell migration-metastasis and evasion of cell death, can be traced back to the ability of p57 KIP2 to stabilize actin cytoskeleton. Potentially, other hallmarks of cancer could also be regulated by p57 KIP2 regulation of the actin cytoskeleton dynamic. Already, increased actin mobility is known to enhance tumor angiogenesis. 36 These findings should increase interest in therapies that reactivate p57 KIP2 expression in cancer cells.
Materials and Methods
Plasmids and siRNA. Myc-LIMK-1 and Myc-LIMK-1 D640A mutant in the FPC1 vector were gifts from K Mizuno (Tohoku University, Japan). Actin-GFP plasmid was a gift from Pirta Hotulainen (University of Helsinki, Finland). GFP plasmid was from Clontech (Invitrogen, Carlsbad, CA, USA). SMARTPool siRNA against LIMK-1 and non-targeted sequence were purchased from Dharmacon (Lafayette, CO, USA).
Cell culture, transfections, and treatments. Human cervical carcinoma HeLa cells expressing p57 KIP2 under the control of the tetracycline promoter (HeLa-p57 KIP2 ) were a gift from S Okret, Karolinska Institutet and were cultured in MEM medium (Gibco, Carlsbad, CA, USA) supplemented with 10% Fetal bovine serum, penicillin/streptomycin, non-essential amino acids, sodium pyruvate, and L-glutamine. 2 mg/ml Dox was added to the culture medium for 24 h to induce expression of p57 KIP2 . Transfections were performed with Lipofectamine and Plus reagent (Invitrogen) according to the manufacturer's protocol. Cells were treated with 0.1 mM Jasp, 1 mM Cytochalsin D, or 0.1 mM STS for the indicated times.
Protein extracts and immunoblotting. Cells were harvested and lysed by sonication in NP40 lysis buffer containing protease inhibitors. 17 Protein lysates were heated to 95 1C for 5 min in Laemmli buffer. In all, 20-40 mg proteins were electrophoresed on 12% SDS-PAGE acrylamide gels, and then immunoblotted onto nitrocellulose membrane. Membranes were blocked in 5% milk and incubated with anti-PARP (BD Pharmingen, Franklin Lakes, NJ, USA), anti-p57 KIP2 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-HK-1 (N-19, Santa Cruz Biotechnology), anti-GFP (Santa Cruz Biotechnology), anti-translocase of outer membrane 40 (tom40; Santa Cruz Biotechnology), or anti-glycerol 3 phosphate dehydrogenase (G3PDH; Trevigen, Gaithersburg, MD, USA) overnight at 4 1C, followed by incubation with the appropriate horseradish peroxidase secondary antibody (1 : 10 000) for 1 h at room temperature. Bands were visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA) following the manufacturers protocol.
Fluorescence recovery after photobleaching (FRAP). FRAP was used to assess the amount of mobile actin-GFP monomers. HeLa-p57 KIP2 cells, grown on glass chamber slides, were transfected with actin-GFP and treated as indicated in the figure legends. Chamber slides were then placed in the POCchamber/CTI Controller/heating insert P system for live cell imaging. After bleaching the region of interest (ROI) with 100% intensity of Argon/2 laser 488 nm (current 4. KIP2 cells were transfected with HK-1-GFP or pcDNA and grown in the presence or absence of Dox for 24 h. Overexpression of HK-1-GFP was analyzed by immunoblotting with GFP, using Tom40 as a loading control, and (c) cleaved caspase-3 staining was assessed by flow cytometry Detection of F-actin. To visualize F-actin, cells grown on glass coverslips were fixed and incubated with rhodamine-conjugated phalloidin (1 : 8000) for 30 min at room temperature. Nuclei were stained by incubating coverslips in 1 mg/ml Hoechst (Molecular Probes) for 10 min at room temperature. Cells were visualized using a 510 Meta confocal microscope (Zeiss).
Measurement of cleaved caspase-3. Cells were fixed with 4% paraformaldehyde for 10 min at 37 1C and permeabilized with 90% methanol for 30 min at À 20 1C. Cells were incubated in blocking solution (0.5% BSA in PBS) for 10 min at room temperature, followed by anti-cleaved caspase-3 (Cell signaling, Danvers, MA, USA; 1 : 3200 in blocking solution) for 1 h at room temperature, and then with goat anti-rabbit Alexa 488 (Invitrogen; 1 : 200 in blocking solution) for 30 min. Cells were washed once in blocking solution between all antibody incubations, and were finally resuspended in PBS for analysis on a FACSCalibur (Becton Dickinson) flow cytometer. Results were analyzed using CellQuest software.
Statistical analysis. Statistical analyses were performed using two tailed, paired student's t-test where *Po0.05 and **Po0.01 were considered to be significant. Bars and error bars represent mean with S.E.M.
